Papilloma in Biological Technology

LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record

... to enhance immune response. Profectus' broad product pipeline will address Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human papilloma Virus (HPV) and Herpes Simplex Virus (HSV). The Profectus portfolio has received over $100 million in funding from multiple sources including ...

CBDM.T, The Market and Business Intelligence Company Reviews The Vaccine Market

... the fastest growing pharmaceutical product categories at over 17% per annum to 2012. This is driven largely by strong growth of HPV vaccines (Human papilloma Virus,Cervarix and Gardasil), paediatric vaccines (Rotarix) launched into developing markets and meningitis vaccines (Prevnar, Menactra), the ...

Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions

... of age and will present with a cytological diagnosis of Pap IIID, a colposcopic diagnosis of mild to moderate cervical dysplasia and confirmed human papilloma virus ("HPV") positive status. The clinical study will be conducted under the direction of Prof. Dr. med. Achim Schneider M.P.H., a world ...

PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies

... promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy ...

Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo

... agreement. We believe our success with this work, along with progress in our other development programs for Familial Polyposis (FAP) and Human papilloma Virus (HPV), demonstrate the potential of our tkRNAi technology to become an important tool to better understand, and ultimately, to treat many ...

AMDL Announces First Quarter 2008 Results Posting Sales of $3.58 Million

... and opportunities referenced above include: -- FY2007 Sales of $15 Million and Gross Profits of $8.1 million; -- In-licensed MyGene's Human papilloma Virus (HPV) Diagnostic Test; -- Signed LOI for the purchase of a China based pharmaceutical distribution company with $28.55 million in ...

AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries

... with MyGene International, Inc. ("MGI," USA) for the MyGene HPV Chip Kit, a diagnostic product for in-vitro genotype testing in women with the Human papilloma Virus (HPV). The agreement between MGI and AMDL is an exclusive sublicense to use the patents, trademark, and technology in manufacturing, promoting, ...

Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development

... aimed at the development, registration and commercialisation of Transgene's therapeutic vaccines developed to fight diseases caused by the Human papilloma Virus. Transgene received an upfront payment and a regulatory milestone of EUR23m in June 2007 and may receive further payments of up to EUR195m ...

Survey Shows Most Women Can't Separate Fact From Fiction When It Comes to Cervical Cancer Prevention

... . The survey was supported by QIAGEN. 1. J. Cuzick, G. Ronco, N. Segnan, P. Giorgio-Rossi et al, "Human papilloma Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial." The ...

Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15%

... patients 18 years and older. Veregen(TM) has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of Veregen(TM) on open wounds. Safety and efficacy of Veregen(TM) have not ...

Helix BioPharma Chairman resigns

... technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus, and its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma. Helix is listed on the Toronto Stock Exchange under ...

Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB

... The burden of illness of cancer: economic cost and quality of life. Annual Review of Public Health 2001;22:91-113. (5) Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. The Lancet, Volume 355, Issue 9222, ...

Third Wave files patent suits against Digene, Chiron and Bayer

... in Madison. The company last Friday filed suit against Digene Corp., seeking a court ruling supporting Third Wave's right to sell its human papilloma virus (HPV) products. On Tuesday, Third Wave filed suit against Chiron Corp. , Bayer Corp., and Bayer HealthCare LLC asking for a similar ...

Third Wave agrees to drop Chiron, Bayer patent lawsuits

... to litigate the suit. The company reached an agreement with Digene Corp. in January under which the companies agreed not to bring suit over human papilloma virus, or HPV, patents against one another for one year. Third Wave develops and markets molecular diagnostic reagents for a variety of DNA and ...

Third Wave reports another loss, stronger sales

... testing. The company said its current product pipeline remains on track or ahead of schedule, including the scheduled submission of two human papilloma virus (HPV) products to the United States Food and Drug Administration in 2007. The company anticipates submitting to the FDA a 14-type, high-risk ...

Third Wave responds to Digene patent lawsuit

... to a lawsuit filed by Digene Corp. , Third Wave Technologies said it has not violated a patent covering a single and rare type of the human papilloma virus (HPV) and would continue to develop products to detect high-risk infections. The lawsuit alleges that Third Wave is infringing on claims of ...

Stratagene to pay Third Wave $10.75M in patent case

... of ongoing litigation, and provide the freedom necessary to expand its molecular diagnostic offerings - including products to screen for the human papilloma virus . In addition, the companies will either seek dismissal without prejudice or an extension of the trial date for Stratagene's ...

Third Wave files countersuit vs. Digene in patent case

... Wave's latest response includes counterclaims against Digene, alleging that it has abused its monopoly power to thwart competition in the human papilloma virus (HPV) diagnostic market. Digene is a molecular diagnostics company based in Gaithersburg, Md. Both Digene and Third Wave make DNA and RNA ...